市場調査レポート

商品コード

1722098

ファージ療法市場：標的細菌別、適応症別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年

Phage Therapy Market Assessment, By Targeted Bacteria, By Indication, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日: 2025年05月09日
発行: Market Xcel - Markets and Data
ページ情報: 英文 250 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 657,360円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 832,656円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,197,856円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.08円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のファージ療法の市場規模は、2025年～2032年の予測期間中に3.73％のCAGRで拡大し、2024年の15億800万米ドルから2032年には20億2,185万米ドルに成長すると予測されています。抗生物質耐性感染症の世界の脅威の高まりは、臨床研究や規制当局の支援の増加と相まって、ファージ療法市場の成長を促進しています。精密医療と遺伝子工学の技術的進歩が、ファージの有効性と治療のカスタマイズ性を高めています。さらに、北米と欧州におけるヘルスケア投資の拡大が、製品開拓と市場導入を加速させています。

2023年6月、Adaptive Phage Therapeuticsは、同社の先駆的なファージ療法プラットフォームをさらに発展させるため、Deerfield Management社とAMR Action Fundが監督するファンドから1,200万米ドルの投資を受けました。

当レポートでは、世界のファージ療法市場について調査し、市場の概要とともに、標的細菌別、適応症別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

市場規模分析と予測
市場シェア分析と予測
- 標的細菌別
  - 大腸菌
  - 黄色ブドウ球菌
  - 連鎖球菌
  - 緑膿菌
  - サルモネラ
  - その他の細菌
- 適応症別
  - 尿路感染症
  - 慢性中耳炎
  - 抜歯
  - 慢性潰瘍性大腸炎
  - 骨感染症
  - 創傷および皮膚感染症
  - 嚢胞性線維症
  - その他
- 投与経路別
  - 経口
  - 局所
  - 非経口
- 流通チャネル別
  - 病院薬局
  - 小売薬局
  - オンライン薬局
- 地域別
  - 北米
  - 欧州
  - アジア太平洋
  - 南米
  - 中東・アフリカ
- 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
2024年の市場マップ分析

第5章北米のファージ療法市場の見通し、2018年～2032年

市場規模分析と予測
市場シェア分析と予測
国別市場評価
- 米国
- カナダ
- メキシコ

第6章欧州のファージ療法市場の見通し、2018年～2032年

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
トルコ
ポーランド

第7章アジア太平洋のファージ療法市場の見通し、2018年～2032年

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第8章南米のファージ療法市場の見通し、2018年～2032年

ブラジル
アルゼンチン

第9章中東・アフリカのファージ療法市場の見通し、2018年～2032年

サウジアラビア
アラブ首長国連邦
南アフリカ

第10章需要供給分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第13章 PESTLE分析

第14章価格分析

第15章市場力学

市場の促進要因
市場の課題

第16章市場動向と発展

第17章規制枠組みとイノベーション

規制当局の承認
臨床試験

第18章特許の情勢

第19章ケーススタディ

第20章競合情勢

市場リーダートップ5の競合マトリックス
参入企業トップ5のSWOT分析
市場の主要企業トップ10の情勢
- PhagoMed Biopharma GmbH
- Armata Pharmaceuticals, Inc.
- Eligo Bioscience S.A.S.
- Intralytix, Inc.
- Locus Biosciences Inc.
- MicroPhage, Inc.
- Aziya immunopreparat LLC
- Sensei Biotherapeutics Inc.
- Eliava BioPreparations LTD
- PhagePro, PBC

第21章戦略的提言

第22章調査会社について・免責事項

図表

List of Tables

Table 1. Competition Matrix of Top 5 Market Leaders
Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 2. Global Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 3. Global Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 4. Global Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 5. Global Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 6. Global Phage Therapy Market Share (%), By Region, 2018-2032F
Figure 7. North America Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 8. North America Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 9. North America Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 10. North America Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 11. North America Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 12. North America Phage Therapy Market Share (%), By Country, 2018-2032F
Figure 13. United States Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 14. United States Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 15. United States Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 16. United States Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 17. United States Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 18. Canada Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 19. Canada Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 20. Canada Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 21. Canada Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 22. Canada Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 23. Mexico Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 24. Mexico Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 25. Mexico Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 26. Mexico Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 27. Mexico Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 28. Europe Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 29. Europe Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 30. Europe Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 31. Europe Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 32. Europe Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 33. Europe Phage Therapy Market Share (%), By Country, 2018-2032F
Figure 34. Germany Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 35. Germany Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 36. Germany Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 37. Germany Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 38. Germany Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 39. France Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 40. France Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 41. France Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 42. France Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 43. France Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 44. Italy Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 45. Italy Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 46. Italy Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 47. Italy Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 48. Italy Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 49. United Kingdom Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 50. United Kingdom Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 51. United Kingdom Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 52. United Kingdom Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 53. United Kingdom Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 54. Russia Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 55. Russia Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 56. Russia Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 57. Russia Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 58. Russia Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 59. Netherlands Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 60. Netherlands Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 61. Netherlands Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 62. Netherlands Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 63. Netherlands Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 64. Spain Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 65. Spain Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 66. Spain Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 67. Spain Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 68. Spain Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 69. Turkey Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 70. Turkey Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 71. Turkey Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 72. Turkey Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 73. Turkey Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 74. Poland Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 75. Poland Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 76. Poland Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 77. Poland Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 78. Poland Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 79. South America Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 80. South America Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 81. South America Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 82. South America Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 83. South America Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 84. South America Phage Therapy Market Share (%), By Country, 2018-2032F
Figure 85. Brazil Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 86. Brazil Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 87. Brazil Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 88. Brazil Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 89. Brazil Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 90. Argentina Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 91. Argentina Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 92. Argentina Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 93. Argentina Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 94. Argentina Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 95. Asia-Pacific Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 96. Asia-Pacific Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 97. Asia-Pacific Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 98. Asia-Pacific Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 99. Asia-Pacific Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 100. Asia-Pacific Phage Therapy Market Share (%), By Country, 2018-2032F
Figure 101. India Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 102. India Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 103. India Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 104. India Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 105. India Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 106. China Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 107. China Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 108. China Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 109. China Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 110. China Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 111. Japan Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 112. Japan Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 113. Japan Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 114. Japan Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 115. Japan Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 116. Australia Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 117. Australia Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 118. Australia Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 119. Australia Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 120. Australia Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 121. Vietnam Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 122. Vietnam Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 123. Vietnam Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 124. Vietnam Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 125. Vietnam Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 126. South Korea Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 127. South Korea Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 128. South Korea Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 129. South Korea Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 130. South Korea Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 131. Indonesia Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 132. Indonesia Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 133. Indonesia Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 134. Indonesia Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 135. Indonesia Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 136. Philippines Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 137. Philippines Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 138. Philippines Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 139. Philippines Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 140. Philippines Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 141. Middle East & Africa Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 142. Middle East & Africa Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 143. Middle East & Africa Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 144. Middle East & Africa Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 145. Middle East & Africa Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 146. Middle East & Africa Phage Therapy Market Share (%), By Country, 2018-2032F
Figure 147. Saudi Arabia Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 148. Saudi Arabia Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 149. Saudi Arabia Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 150. Saudi Arabia Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 151. Saudi Arabia Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 152. UAE Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 153. UAE Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 154. UAE Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 155. UAE Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 156. UAE Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 157. South Africa Phage Therapy Market, By Value, In USD Million, 2018-2032F
Figure 158. South Africa Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
Figure 159. South Africa Phage Therapy Market Share (%), By Indication, 2018-2032F
Figure 160. South Africa Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
Figure 161. South Africa Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
Figure 162. By Targeted Bacteria Map-Market Size (USD Million) & Growth Rate (%), 2024
Figure 163. By Indication Map-Market Size (USD Million) & Growth Rate (%), 2024
Figure 164. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2024
Figure 165. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2024
Figure 166. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024

Product Code: MX13076

Global phage therapy market is projected to witness a CAGR of 3.73% during the forecast period 2025-2032, growing from USD 1508 million in 2024 to USD 2021.85 million in 2032. The rising global threat of antibiotic-resistant infections, coupled with increasing clinical research and regulatory support, is driving the growth of the phage therapy market. Technological advancements in precision medicine and genetic engineering are enhancing phage efficacy and treatment customization. Additionally, growing healthcare investments across North America and Europe are accelerating product development and market adoption.

In June 2023, Adaptive Phage Therapeutics secured an investment of USD 12 million from funds overseen by Deerfield Management and the AMR Action Fund to further develop their pioneering phage therapy platform.

Rising Global Concern Over Antibiotic Resistance

The escalating challenge of antibiotic resistance is a major factor propelling the global phage therapy market. Conventional antibiotics are increasingly ineffective against resistant bacterial strains, resulting in extended illnesses, increased healthcare expenses, and higher mortality rates. Phage therapy presents a precise and innovative method by utilizing bacteriophages to specifically target and eliminate pathogenic bacteria while preserving beneficial microorganisms. This targeted approach minimizes the collateral damage typically associated with antibiotics and improves patient outcomes. Health authorities around the world are advocating research investments in alternative antimicrobial strategies. Furthermore, partnerships between biotechnology companies and healthcare organizations are expediting clinical trials for phage therapies. This intensified emphasis on alternatives is fostering a conducive environment for market growth. For example, in February 2025, the World Health Organization (WHO) highlighted the urgent need for alternatives such as phage therapy in its Global Antimicrobial Resistance and Use Surveillance System (GLASS) report.

Rapid Advancements in GLP-1 and Multi-Target Therapeutics

The advancement of segment-specific innovation is propelling the growth of the phage therapy market, particularly through the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists. These therapies facilitate weight loss by increasing feelings of fullness and decreasing appetite, while also providing metabolic advantages such as improved glycemic control. Pharmaceutical companies are currently investigating multi-target medications that integrate GLP-1, amylin, or GIP mechanisms to enhance therapeutic outcomes. As new drug candidates exhibit greater efficacy in clinical trials compared to previous therapies, the interest in this mechanism of action is steadily increasing. This trend is leading to a surge in investments in clinical research and development, expansion of drug pipelines, and expedited regulatory processes for innovative medications. For example, in December 2023, Armata Pharmaceuticals reported favorable Phase Ib/IIa clinical trial outcomes for its phage therapy candidate AP-PA02 aimed at treating Pseudomonas aeruginosa infections.

Rising Investments and Positive Clinical Trial Results Accelerating Phage Therapy Development

The global market for phage therapy is experiencing significant growth, driven by increased investments and successful clinical results, especially in combating drug-resistant bacterial infections. Favorable outcomes from clinical trials of engineered phage therapies are motivating regulatory agencies and funding organizations to enhance their support for research and development initiatives. The emphasis on precision-targeted treatments is becoming essential as the prevalence of multidrug-resistant infections escalates globally. This development not only enhances the reputation of phage therapies among healthcare professionals but also expedites their journey towards commercialization. Additionally, financial backing from government entities highlights the promise of phage-based therapies as a legitimate alternative to traditional antibiotics, opening new opportunities for biotechnology companies. For instance, Locus Biosciences, Inc. ("Locus"), a clinical-stage biotechnology company that is at the forefront of developing a new class of precision-engineered bacteriophage therapies for various bacterial infections, announced positive results from Part 1 of its two-part Phase 2 ELIMINATE trial. This Phase 2 investigation is evaluating LBP-EC01, a CRISPR-Cas3 genetically modified bacteriophage therapy designed to treat uncomplicated urinary tract infections (uUTIs) caused by antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli).

North America Maintains Market Leadership

North America leads the global phage therapy market, primarily due to substantial research funding, a well-established healthcare system, and active institutional backing. This region is home to numerous prominent phage therapy developers, academic research institutions, and government initiatives that promote antimicrobial innovation. Agencies such as the NIH, BARDA, and CARB-X are making significant investments in phage research programs to address the challenges posed by antibiotic resistance. Furthermore, there is an increasing trend among hospitals in the United States and Canada to engage in collaborative clinical trials assessing phage therapies for compassionate use. The combination of a strong regulatory environment and the rising incidence of multidrug-resistant infections ensures that North America will continue to hold its dominant position. In September 2023, the National Institutes of Health (NIH) awarded USD 5.7 million to the J. Craig Venter Institute (JCVI) to support a project focused on developing a phage therapeutic cocktail for treating antibiotic-resistant Klebsiella pneumoniae infections.

Future Market Scenario (2025-2032F)

The global market for phage therapy is set to experience significant expansion in the coming decade, fueled by the pressing demand for alternatives to traditional antibiotics in light of escalating antimicrobial resistance. As advancements in precision medicine continue, phage therapy's ability to selectively target bacteria while preserving healthy microbiota positions it as a highly promising solution. An increase in clinical trials, regulatory backing, and investments in biotechnological innovation are anticipated to broaden its therapeutic applications in areas such as infectious diseases, chronic wounds, and cystic fibrosis. Furthermore, technological advancements, including engineered phages and customized phage cocktails, are expected to improve treatment effectiveness. With North America and Europe at the forefront of research and regulatory approvals, emerging markets in the Asia-Pacific region are also making significant investments, paving the way for wider commercialization opportunities by the early 2030s.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of phage therapy and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, in May 2023, Adaptive Phage Therapeutics established a licensing agreement with the Phage Therapy Center (IPTC) at the Hebrew University of Jerusalem and Hadassah Medical Center, aimed at identifying multiple phages that exhibit remarkably extensive efficacy against antibiotic-resistant bacteria.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Phage Therapy Market Outlook, 2018-2032F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Targeted Bacteria
  - 4.2.1.1. Escherichia coli
  - 4.2.1.2. Staphylococcus aureus
  - 4.2.1.3. Streptococcus
  - 4.2.1.4. Pseudomonas aeruginosa
  - 4.2.1.5. Salmonella
  - 4.2.1.6. Other Bacteria
- 4.2.2. By Indication
  - 4.2.2.1. Urinary Tract Infections
  - 4.2.2.2. Chronic Otitis
  - 4.2.2.3. Dental Extraction
  - 4.2.2.4. Chronic Ulcerative Colitis
  - 4.2.2.5. Bone Infection
  - 4.2.2.6. Wound and Skin Infections
  - 4.2.2.7. Cystic Fibrosis
  - 4.2.2.8. Others
- 4.2.3. By Route of Administration
  - 4.2.3.1. Oral
  - 4.2.3.2. Topical
  - 4.2.3.3. Parenteral
- 4.2.4. By Distribution Channel
  - 4.2.4.1. Hospital Pharmacies
  - 4.2.4.2. Retail Pharmacies
  - 4.2.4.3. Online Pharmacies
- 4.2.5. By Region
  - 4.2.5.1. North America
  - 4.2.5.2. Europe
  - 4.2.5.3. Asia-Pacific
  - 4.2.5.4. South America
  - 4.2.5.5. Middle East and Africa
- 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
4.3. Market Map Analysis, 2024
- 4.3.1. By Targeted Bacteria
- 4.3.2. By Indication
- 4.3.3. By Route of Administration
- 4.3.4. By Distribution Channel
- 4.3.5. By Region

5. North America Phage Therapy Market Outlook, 2018-2032F

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Targeted Bacteria
  - 5.2.1.1. Escherichia coli
  - 5.2.1.2. Staphylococcus aureus
  - 5.2.1.3. Streptococcus
  - 5.2.1.4. Pseudomonas aeruginosa
  - 5.2.1.5. Salmonella
  - 5.2.1.6. Other Bacteria
- 5.2.2. By Indication
  - 5.2.2.1. Urinary Tract Infections
  - 5.2.2.2. Chronic Otitis
  - 5.2.2.3. Dental Extraction
  - 5.2.2.4. Chronic Ulcerative Colitis
  - 5.2.2.5. Bone Infection
  - 5.2.2.6. Wound and Skin Infections
  - 5.2.2.7. Cystic Fibrosis
  - 5.2.2.8. Others
- 5.2.3. By Route of Administration
  - 5.2.3.1. Oral
  - 5.2.3.2. Topical
  - 5.2.3.3. Parenteral
- 5.2.4. By Distribution Channel
  - 5.2.4.1. Hospital Pharmacies
  - 5.2.4.2. Retail Pharmacies
  - 5.2.4.3. Online Pharmacies
- 5.2.5. By Country Share
  - 5.2.5.1. United States
  - 5.2.5.2. Canada
  - 5.2.5.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Phage Therapy Market Outlook, 2018-2032F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Targeted Bacteria
      - 5.3.1.2.1.1. Escherichia coli
      - 5.3.1.2.1.2. Staphylococcus aureus
      - 5.3.1.2.1.3. Streptococcus
      - 5.3.1.2.1.4. Pseudomonas aeruginosa
      - 5.3.1.2.1.5. Salmonella
      - 5.3.1.2.1.6. Other Bacteria
    - 5.3.1.2.2. By Indication
      - 5.3.1.2.2.1. Urinary Tract Infections
      - 5.3.1.2.2.2. Chronic Otitis
      - 5.3.1.2.2.3. Dental Extraction
      - 5.3.1.2.2.4. Chronic Ulcerative Colitis
      - 5.3.1.2.2.5. Bone Infection
      - 5.3.1.2.2.6. Wound and Skin Infections
      - 5.3.1.2.2.7. Cystic Fibrosis
      - 5.3.1.2.2.8. Others
    - 5.3.1.2.3. By Route of Administration
      - 5.3.1.2.3.1. Oral
      - 5.3.1.2.3.2. Topical
      - 5.3.1.2.3.3. Parenteral
    - 5.3.1.2.4. By Distribution Channel
      - 5.3.1.2.4.1. Hospital Pharmacies
      - 5.3.1.2.4.2. Retail Pharmacies
      - 5.3.1.2.4.3. Online Pharmacies
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Phage Therapy Market Outlook, 2018-2032F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Turkey
6.9. Poland

7. Asia-Pacific Phage Therapy Market Outlook, 2018-2032F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Phage Therapy Market Outlook, 2018-2032F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Phage Therapy Market Outlook, 2018-2032F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

15.1. Market Drivers
15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

17.1. Regulatory Approvals
17.2. Clinical Trials

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

20.1. Competition Matrix of Top 5 Market Leaders
20.2. SWOT Analysis for Top 5 Players
20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. PhagoMed Biopharma GmbH
  - 20.3.1.1. Company Details
  - 20.3.1.2. Key Management Personnel
  - 20.3.1.3. Products and Services
  - 20.3.1.4. Financials (As Reported)
  - 20.3.1.5. Key Market Focus and Geographical Presence
  - 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 20.3.2. Armata Pharmaceuticals, Inc.
- 20.3.3. Eligo Bioscience S.A.S.
- 20.3.4. Intralytix, Inc.
- 20.3.5. Locus Biosciences Inc.
- 20.3.6. MicroPhage, Inc.
- 20.3.7. Aziya immunopreparat LLC
- 20.3.8. Sensei Biotherapeutics Inc.
- 20.3.9. Eliava BioPreparations LTD
- 20.3.10. PhagePro, PBC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

ファージ療法市場：標的細菌別、適応症別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年

Phage Therapy Market Assessment, By Targeted Bacteria, By Indication, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のファージ療法市場の見通し、2018年～2032年

第5章 北米のファージ療法市場の見通し、2018年～2032年

第6章 欧州のファージ療法市場の見通し、2018年～2032年

第7章 アジア太平洋のファージ療法市場の見通し、2018年～2032年

第8章 南米のファージ療法市場の見通し、2018年～2032年

第9章 中東・アフリカのファージ療法市場の見通し、2018年～2032年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析